Published in Am J Pathol on June 01, 2003
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol (2009) 7.34
New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol (2009) 3.83
Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest (2011) 2.43
Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. Am J Pathol (2004) 2.09
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.07
The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med (2007) 1.88
Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol (2009) 1.75
The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J (2006) 1.72
Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens (2012) 1.46
Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J Am Soc Nephrol (2009) 1.45
Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine (2008) 1.30
Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care (2007) 1.23
Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol (2012) 1.20
Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol (2010) 1.17
Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) (2008) 1.15
Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol (2012) 1.11
Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost (2009) 1.10
Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer (2007) 1.09
Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol (2008) 1.07
Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. Mol Biol Cell (2008) 1.05
Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta (2011) 1.01
Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am J Physiol Renal Physiol (2011) 0.99
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation. Cell Death Dis (2013) 0.98
Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment. J Physiol (2014) 0.97
Molecular mechanisms of renal blood flow autoregulation. Curr Vasc Pharmacol (2014) 0.92
Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol (2008) 0.92
Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J Nephrol (2013) 0.91
KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis. Nephrol Dial Transplant (2013) 0.90
Temporal characterization of the development of renal injury in FHH rats and FHH.1BN congenic strains. Am J Physiol Renal Physiol (2010) 0.88
Epithelial-mesenchymal transition: An emerging target in tissue fibrosis. Exp Biol Med (Maywood) (2015) 0.86
Deficient degradation of homotrimeric type I collagen, α1(I)3 glomerulopathy in oim mice. Mol Genet Metab (2011) 0.85
Transition of mesothelial cell to fibroblast in peritoneal dialysis: EMT, stem cell or bystander? Perit Dial Int (2015) 0.85
A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem (2014) 0.84
Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetol Metab Syndr (2014) 0.84
Parathyroid hormone-related protein promotes epithelial-mesenchymal transition. J Am Soc Nephrol (2009) 0.84
RBP2 induces epithelial-mesenchymal transition in non-small cell lung cancer. PLoS One (2013) 0.83
Progression of kidney disease in non-diabetic patients with coronary artery disease: predictive role of circulating matrix metalloproteinase-2, -3, and -9. PLoS One (2013) 0.82
Vitamin a deficiency and alterations in the extracellular matrix. Nutrients (2014) 0.82
An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol (2012) 0.82
Amelioration of glomerulosclerosis with all-trans retinoic acid is linked to decreased plasminogen activator inhibitor-1 and α-smooth muscle actin. Acta Pharmacol Sin (2011) 0.81
Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small molecule. Bioinformatics (2008) 0.81
Activation of the TGFβ pathway impairs endothelial to haematopoietic transition. Sci Rep (2016) 0.80
Phthalimide neovascular factor 1 (PNF1) modulates MT1-MMP activity in human microvascular endothelial cells. Biotechnol Bioeng (2009) 0.80
Macrophages During the Fibrotic Process: M2 as Friend and Foe. Front Immunol (2015) 0.79
An in vitro model for the pro-fibrotic effects of retinoids: mechanisms of action. Br J Pharmacol (2013) 0.79
Ochratoxin A-induced renal cortex fibrosis and epithelial-to-mesenchymal transition: molecular mechanisms of ochratoxin A-injury and potential effects of red wine. Mol Med (2006) 0.79
Protein-bound uremic toxins induce tissue remodeling by targeting the EGF receptor. J Am Soc Nephrol (2014) 0.78
A transgenic mouse model for studying the role of the parathyroid hormone-related protein system in renal injury. J Biomed Biotechnol (2010) 0.77
Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed) (2015) 0.76
Molecular mechanisms of suberoylanilide hydroxamic acid in the inhibition of TGF-β1-mediated canine corneal fibrosis. Vet Ophthalmol (2015) 0.76
Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT). Purinergic Signal (2016) 0.75
Role of matrix metalloproteinases in radiation-induced lung injury in alveolar epithelial cells of Bama minipigs. Exp Ther Med (2015) 0.75
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol (2017) 0.75
Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy. PLoS One (2017) 0.75
Renoprotective action of a matrix metalloproteinase inhibitor in progressive mesangioproliferative nephritis. Nephron Extra (2012) 0.75
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem (2017) 0.75
Fuzheng Huayu Formula () prevents rat renal interstitial fibrosis induced by HgCl2 via antioxidative stress and down-regulation of nuclear factor-kappa B activity. Chin J Integr Med (2017) 0.75
Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol (1993) 8.36
Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol (1999) 4.99
Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science (1997) 4.83
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature (1990) 4.64
Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol (2001) 4.39
Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol (1997) 4.22
Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A (2001) 4.20
Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature (1992) 3.96
Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem (1997) 3.74
Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol (2000) 3.34
Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int (1999) 3.09
Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol (2001) 2.95
Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol (2000) 2.94
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science (1999) 2.62
Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest (1996) 2.42
Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J (2000) 2.41
Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int (1998) 2.35
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol (2001) 2.18
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol (1997) 2.10
TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int (1997) 2.01
Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev (1996) 2.00
Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem (1996) 1.98
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med (1996) 1.93
Renal injury from angiotensin II-mediated hypertension. Hypertension (1992) 1.88
Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) (1996) 1.84
Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. J Biol Chem (2000) 1.70
Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant (1997) 1.69
The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem (1999) 1.68
Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl (1996) 1.54
Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem (2001) 1.54
Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl (1998) 1.50
Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J (1998) 1.48
Enhanced expression of "muscle-specific" actin in glomerulonephritis. Kidney Int (1992) 1.46
Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res (1996) 1.45
Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines. Kidney Int (1992) 1.44
Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem (1999) 1.41
Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem (1997) 1.39
Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett (1996) 1.37
Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem (1996) 1.35
Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol (1994) 1.33
Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J Clin Pathol (1997) 1.28
Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem (1996) 1.25
MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function. J Biol Chem (2001) 1.23
Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int (1997) 1.21
Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest (1995) 1.21
Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions. Dev Biol (2000) 1.20
Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int (1996) 1.19
Myofibroblasts, predictors of progression of mesangial IgA nephropathy? Nephrol Dial Transplant (1994) 1.18
Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol (2002) 1.17
Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci (2001) 1.12
Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol (1994) 1.11
A unique substrate recognition profile for matrix metalloproteinase-2. J Biol Chem (2001) 1.10
Transforming growth factor-beta 1 expression and myofibroblast formation during arterial repair. Arterioscler Thromb Vasc Biol (1996) 1.08
Myofibroblasts and the progression of experimental glomerulonephritis. Exp Nephrol (1995) 1.07
Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest (1996) 1.06
Interstitial myofibroblasts in IgA glomerulonephritis. Am J Nephrol (1995) 1.05
Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma. Cancer Res (1991) 1.03
The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases. Clin Nephrol (1992) 1.02
The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli. Functional interpretation of morphologic findings. Klin Wochenschr (1981) 1.00
Myofibroblasts in experimental hydronephrosis. Am J Pathol (1995) 1.00
Low oxygen tension increases mRNA levels of alpha 1 (I) procollagen in human dermal fibroblasts. J Cell Physiol (1993) 0.99
Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol (1997) 0.99
Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem (2001) 0.98
Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of transforming growth factor-beta1, thyroid hormone, angiotensin II and basic fibroblast growth factor. J Mol Cell Cardiol (1997) 0.97
Remnant kidney hypermetabolism and progression of chronic renal failure. Am J Physiol (1988) 0.93
Mechanisms of tubulo-interstitial injury in progressive renal diseases. Eur J Clin Invest (1993) 0.92
Calcium influx inhibits MT1-MMP processing and blocks MMP-2 activation. FEBS Lett (1997) 0.91
Release of biological activities from quiescent fibronectin by a conformational change and limited proteolysis by matrix metalloproteinases. Biochemistry (1995) 0.90
Effects of transforming growth factor-beta on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol (1992) 0.90
Membrane type 1-matrix metalloproteinase expression is regulated by E-cadherin through the suppression of mitogen-activated protein kinase cascade. Cancer Lett (2000) 0.89
Interstitial myofibroblasts in experimental renal infection and scarring. Am J Nephrol (1995) 0.88
Transformation of rat inner medullary fibroblasts to myofibroblasts in vitro. Kidney Int (1997) 0.85
Evidence for C-type natriuretic peptide production in the rat kidney. Biochem Biophys Res Commun (1993) 0.84
Contractile cells of the kidney in primary glomerular disorders: an immunohistochemical study using an anti-alpha-smooth muscle actin monoclonal antibody. Hum Pathol (1993) 0.84
Hypoxia regulates endothelin-1 production by the inner medullary collecting duct. J Lab Clin Med (1998) 0.79
A substrate phage enzyme-linked immunosorbent assay to profile panels of proteases. Anal Biochem (2001) 0.77
Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol (2006) 1.63
Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J (2006) 1.59
Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem (2001) 1.51
Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol (2006) 1.43
Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res (2005) 1.30
A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J (2003) 1.29
Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun (2007) 1.23
Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem (2003) 1.19
Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol (2006) 1.12
The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J (2003) 1.08
Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem (2004) 1.07
Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc Natl Acad Sci U S A (2005) 1.00
Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) (2008) 0.99
Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem (2002) 0.99
Evaluation of Akt/mTOR activity in muscle atrophy after rotator cuff tears in a rat model. J Orthop Res (2012) 0.98
Intraventricular and interventricular cellular heterogeneity of inotropic responses to α(1)-adrenergic stimulation. Am J Physiol Heart Circ Physiol (2013) 0.95
The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J (2005) 0.95
Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int (2005) 0.93
Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol (2008) 0.92
mTOR regulates fatty infiltration through SREBP-1 and PPARγ after a combined massive rotator cuff tear and suprascapular nerve injury in rats. J Orthop Res (2012) 0.91
Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. J Vasc Surg (2005) 0.88
Original article Muscle extracellular matrix degradation and contractibility following tendon rupture and disuse. Muscles Ligaments Tendons J (2013) 0.86
Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). Biochem J (2002) 0.86
Regulation of MMP-2 gene transcription in dermal wounds. J Invest Dermatol (2007) 0.85
Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis. Spine (Phila Pa 1976) (2008) 0.84
Expression of a Gi-coupled receptor in the heart causes impaired Ca2+ handling, myofilament injury, and dilated cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 0.84
Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia. Int J Exp Pathol (2010) 0.84
An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Hum Genet (2006) 0.83
Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol (2010) 0.83
Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells. Reprod Biol Endocrinol (2009) 0.80
Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts. FASEB J (2007) 0.79
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf (2012) 0.78
Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. J Am Soc Nephrol (2002) 0.78
Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochem Biophys Res Commun (2010) 0.78
Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis. J Cardiovasc Pharmacol (2016) 0.76
Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype. Carcinogenesis (2011) 0.75